Tiziana Life Sciences LTD

2:00 PM - 2:15 PM (PDT), Tuesday, June 14, 2022
Tiziana is developing innovative drugs for the treatment of Crohn's Disease, Progressive Multiple Sclerosis (pro-MS) and KRAS+ NSCLC
Ticker:
TLSA
Exchange:
NASDAQ
Company Type:
Publicly Traded Company
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2014
Main Therapeutic Focus:
Lead Product in Development:
Foralumab
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided